References
- Duconge J , RamosAS , ClaudioKet al. A novel admixture-based pharmacogenetic approach to refine warfarin dosing in Caribbean Hispanics . PLoS ONE11 ( 1 ), e0145480 ( 2016 ).
- Ruaño G , DucongeJ , WindemuthAet al. Physiogenomic analysis of the Puerto Rican population . Pharmacogenomics10 ( 4 ), 565 – 577 ( 2009 ).
- Pritchard JK , StephensM , DonnellyP . Inference of population structure using multilocus genotype data . Genetics155 , 945 – 959 ( 2000 ).
- Via M , GignouxC , RothLAet al. History shaped the geographic distribution of genomic admixture on the island of Puerto Rico . PLoS ONE6 , e16513 ( 2011 ).
- Cavallari LH , LangaeeTY , MomaryKMet al. Genetic and clinical predictors of warfarin dose requirements in African Americans . Clin. Pharmacol. Ther.87 , 459 – 464 ( 2010 ).
- Drozda K , WongS , PatelSRet al. Poor warfarin dose prediction with pharmacogenetic algorithms that exclude genotypes important for African Americans . Pharmacogenet. Genomics25 ( 2 ), 73 – 81 ( 2015 ).
- Scott SA , JaremkoM , LubitzSA , KornreichR , HalperinJL , DesnickRJ . CYP2C9*8 is prevalent among African–Americans: implications for pharmacogenetic dosing . Pharmacogenomics10 ( 8 ), 1243 – 1255 ( 2009 ).
- Liu Y , JeongH , TakahashiHet al. Decreased warfarin clearance associated with CYP2C9 R150H (*8) polymorphism . Clin. Pharmacol. Ther.91 ( 4 ), 660 – 665 ( 2012 ).
- International Warfarin Pharmacogenetics Consortium , KleinTE , AltmanRBet al.Estimation of the warfarin dose with clinical and pharmacogenetic data . N. Engl. J. Med.360 , 753 – 764 ( 2009 ).
- Lenzini P , WadeliusM , KimmelSet al. Integration of genetic, clinical, and laboratory data to refine warfarin dosing . Clin. Pharmacol. Ther.87 , 572 – 578 ( 2010 ).
- Bress A , PatelSR , PereraMA , CampbellRT , KittlesRA , CavallariLH . Effect of NQO1 and CYP4F2 genotypes on warfarin dose requirements in Hispanic–Americans and African–Americans . Pharmacogenomics13 ( 16 ), 1925 – 1935 ( 2012 ).
- Duconge J , CadillaCL , SeipRL , RuañoG . Why admixture matters in genetically-guided therapy: missed targets in the COAG and EU-PACT trials . PR Health Sci. J.34 ( 3 ), 175 – 177 ( 2015 ).
- Villagra D , DucongeJ , WindemuthAet al. CYP2C9 and VKORC1 genotypes in Puerto Ricans: a case for admixture-matching in clinical pharmacogenetic studies . Clin. Chim. Acta411 ( 17 ), 1306 – 1311 ( 2010 ).
- Duconge J , RuañoG . Emerging role of admixture in the pharmacogenetics of Puerto Rican Hispanics . J. Pharmacogenom. Pharmacoproteomics1 ( 101 ), pii:1000101 ( 2010 ).
- Duconge J . Population heterogeneity and genomic admixture: relevance for global pharmacogenetics . J. Pharmacogenom. Pharmacoproteomics5 , 5 ( 2014 ). http://dx.doi.org/10.4172/2153-0645.1000e141.
- Suarez-Kurtz G . Pharmacogenomics in Admixed Populations . Landes Bioscience , TX, USA ( 2007 ).
- Suarez-Kurtz G , PenaSD . Pharmacogenomics in the Americas: the impact of genetic admixture . Curr. Drug Targets7 , 1649 – 1658 ( 2006 ).
- Claudio-Campos K , DucongeJ , CadillaCL , RuañoG . Pharmacogenetics of drug metabolizing enzymes in U.S. Hispanics . Drug Metabol. Personal. Ther.30 ( 2 ), 87 – 105 ( 2015 ).